Skip to main content
. Author manuscript; available in PMC: 2021 May 28.
Published in final edited form as: J Alzheimers Dis. 2020;73(4):1597–1606. doi: 10.3233/JAD-190543

Fig. 2.

Fig. 2.

Oligopin prevents oligomerization of full-length tau protein in vitro. (a) SDS-PAGE of tau protein in the presence or absence of 25 (1:1) or 100 (1:4) μM oligopin following PICUP. This panel is composed of two independent results. Lanes 1: molecular weight; Lanes 2 and 6: UnXL, un-cross-linked tau protein; Lanes 3 and 7: XL, cross-linked tau protein; Lanes 5 and 9: tau protein aggregated in the presence of 25 or 100 μ M oligopin. A compound related to oligopin was used as a control to assess attenuation of tau oligomerization (lanes 4 and 8). For each lane in a, the ratios of the integrated densities of each oligomer to the monomer in the lane are shown. The gel is representative of three independent experiments.